IMvigority 011：ctDNA测试可以预测MIBC中的辅助免疫治疗益处

肌肉侵袭性膀胱癌（MIBC）患者的无病生存期（DFS）和总生存期（OS）改善，ctDNA测试可以准确预测哪些患者将受益于免疫疗法atezolumab（Tecentriq）的辅助治疗。IMvigration 011试验的结果非常重要，为分子水平上复发呈阳性但成像上没有疾病证据的膀胱癌患者开辟了新的治疗范式。这些结果预计将在即将举行的医学会议上分享。

来源: urologytimes

原文链接：原文

参考文献

1. IMvigor011 bladder cancer trial achieves positive results, with Signatera strongly predicting adjuvant immunotherapy benefit. News release. Natera, Inc. August 18, 2025. Accessed August 18, 2025. https://www.natera.com/company/news/imvigor011-bladder-cancer-trial-achieves-positive-results-with-signatera-strongly-predicting-adjuvant-immunotherapy-benefit/
2. A study of atezolizumab versus placebo as adjuvant therapy in patients with high-risk muscle-invasive bladder cancer who are ctDNA positive following cystectomy (IMvigor011). ClinicalTrials.gov. Last updated June 22, 2025. Accessed August 18, 2025. https://clinicaltrials.gov/study/NCT04660344
3. Natera announces positive surveillance analysis from the randomized phase III IMvigor011 trial in muscle-invasive bladder cancer. News release. Natera, Inc. April 5, 2024. Accessed August 18, 2025. https://www.natera.com/company/news/natera-announces-positive-surveillance-analysis-from-the-randomized-phase-iii-imvigor011-trial-in-muscle-invasive-bladder-cancer/